In last trading session, Neumora Therapeutics Inc (NASDAQ:NMRA) saw 1.03 million shares changing hands with its beta currently measuring 2.89. Company’s recent per share price level of $0.94 trading at $0.03 or 2.97% at ring of the bell on the day assigns it a market valuation of $152.33M. That closing price of NMRA’s stock is at a discount of -1728.72% from its 52-week high price of $17.19 and is indicating a premium of 4.26% from its 52-week low price of $0.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.1 million shares which gives us an average trading volume of 3.29 million if we extend that period to 3-months.
For Neumora Therapeutics Inc (NMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.44. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Upright in the green during last session for gaining 2.97%, in the last five days NMRA remained trading in the red while hitting it’s week-highest on Friday, 03/28/25 when the stock touched $0.94 price level, adding 16.44% to its value on the day. Neumora Therapeutics Inc’s shares saw a change of -91.13% in year-to-date performance and have moved -13.72% in past 5-day. Neumora Therapeutics Inc (NASDAQ:NMRA) showed a performance of -33.30% in past 30-days. Number of shares sold short was 12.89 million shares which calculate 9.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 68.67% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -112.77% in reaching the projected high whereas dropping to the targeted low would mean a loss of -112.77% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 4.29% while estimates for its earnings growth in next 5 years are of 8.30%.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders are in possession of 27.52% of company’s total shares while institution are holding 71.99 percent of that, with stock having share float percentage of 99.33%. Investors also watch the number of corporate investors in a company very closely, which is 71.99% institutions for Neumora Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at NMRA for having 8.62 million shares of worth $84.76 million. And as of 2024-06-30, it was holding 5.4235 of the company’s outstanding shares.
The second largest institutional holder is SOFTBANK GROUP CORP., which was holding about 7.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.8099 of outstanding shares, having a total worth of $75.17 million.
On the other hand, SMALLCAP WORLD FUND INC and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.7 shares of worth $3.48 million or 2.28% of the total outstanding shares. The later fund manager was in possession of 2.32 shares on Dec 31, 2024 , making its stake of worth around $2.18 million in the company or a holder of 1.43% of company’s stock.
